WallStreetZenWallStreetZen

NASDAQ: IMVT
Immunovant Inc Stock

$32.52+1.09 (+3.47%)
Updated Mar 27, 2024
IMVT Price
$32.52
Fair Value Price
$3.05
Market Cap
$4.72B
52 Week Low
$14.05
52 Week High
$45.58
P/E
-17.77x
P/B
6.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$243.45M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$210M
Beta
0.88
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

IMVT Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMVT ($32.52) is overvalued by 966.42% relative to our estimate of its Fair Value price of $3.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMVT ($32.52) is not significantly undervalued (966.42%) relative to our estimate of its Fair Value price of $3.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMVT due diligence checks available for Premium users.

Be the first to know about important IMVT news, forecast changes, insider trades & much more!

IMVT News

Valuation

IMVT fair value

Fair Value of IMVT stock based on Discounted Cash Flow (DCF)
Price
$32.52
Fair Value
$3.05
Overvalued by
966.42%
IMVT ($32.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMVT ($32.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IMVT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-17.77x
Industry
14.3x
Market
44.45x

IMVT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.96x
Industry
6.2x
IMVT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMVT's financial health

Profit margin

Revenue
$0.0
Net Income
-$51.4M
Profit Margin
0%
IMVT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$711.4M
Liabilities
$32.1M
Debt to equity
0.05
IMVT's short-term assets ($710.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMVT's short-term assets ($710.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMVT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$47.1M
Investing
-$131.0k
Financing
$469.8M
IMVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMVT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IMVT$4.72B+3.47%-17.77x6.96x
BHVN$4.65B+1.30%-9.95x10.87x
NUVL$4.91B+1.19%-35.32x7.01x
KRYS$5.01B+1.74%443.00x6.44x
MDGL$5.15B+4.52%-12.95x12.70x

Immunovant Stock FAQ

What is Immunovant's quote symbol?

(NASDAQ: IMVT) Immunovant trades on the NASDAQ under the ticker symbol IMVT. Immunovant stock quotes can also be displayed as NASDAQ: IMVT.

If you're new to stock investing, here's how to buy Immunovant stock.

What is the 52 week high and low for Immunovant (NASDAQ: IMVT)?

(NASDAQ: IMVT) Immunovant's 52-week high was $45.58, and its 52-week low was $14.05. It is currently -28.65% from its 52-week high and 131.46% from its 52-week low.

How much is Immunovant stock worth today?

(NASDAQ: IMVT) Immunovant currently has 145,292,970 outstanding shares. With Immunovant stock trading at $32.52 per share, the total value of Immunovant stock (market capitalization) is $4.72B.

Immunovant stock was originally listed at a price of $10.26 in May 10, 2019. If you had invested in Immunovant stock at $10.26, your return over the last 4 years would have been 216.96%, for an annualized return of 33.43% (not including any dividends or dividend reinvestments).

How much is Immunovant's stock price per share?

(NASDAQ: IMVT) Immunovant stock price per share is $32.52 today (as of Mar 27, 2024).

What is Immunovant's Market Cap?

(NASDAQ: IMVT) Immunovant's market cap is $4.72B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Immunovant's market cap is calculated by multiplying IMVT's current stock price of $32.52 by IMVT's total outstanding shares of 145,292,970.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.